Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 991-1000 Newer>

Managed Care January 2004	Increasing drug copayments deter compliance Raising copayments in tiered prescription drug plans increases the likelihood that patients will stop taking prescribed medications, according to a recent study published in the New England Journal of Medicine.
Managed Care January 2004 Michael S. Victoroff	Logic Flies When EMRs Debated A chance encounter with an unhappy reader (a physician) spurs a flood cliches about why doctors are "justified" in their refusal to move out of the dark ages
Managed Care January 2004	Major legislative reform not in store for 2004 It appears that health care reform will reside with health care organizations, according to a new Cap Gemini Ernst & Young forecast.
CIO February 1, 2004 Stephanie Overby	Can't We All Just Get Along? IT and business units at Novartis weren't talking to one another -- until they started speaking a common language of leadership
BusinessWeek February 9, 2004 Gene G. Marcial	Telik's Promising Tumor Treatments Telik, which develops drugs for cancer -- mainly chemotherapy-resistant solid tumors -- and diabetes may be the next biotech buyout. So says Mark Monane of investment outfit Needham, who identified Esperion Therapeutics in early December as buyout bait.
The Motley Fool January 27, 2004 Jeff Hwang	Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings.
The Motley Fool January 27, 2004 David Nierengarten	Pfizer's Next Target? Esperion, swallowed by Pfizer last year, shares many similarities with Atherogenics. Investors in the latter, however, should not count on being acquired any time soon by a big pharmaceutical company.
The Motley Fool January 26, 2004 Alyce Lomax	Amerisource's Fightin' Words Wholesale drug distributor AmerisourceBergen's first-quarter profits rise, but will a fight with veterans end peacefully?
BusinessWeek February 2, 2004 Kerry Capell	Aventis: Investors Await Their Reward Debt is down, margins are up. So why is the drugmaker's stock lagging its peers?
InternetNews January 23, 2004 Michael Singer	Oracle Makes a Play for Life Sciences The business software giant acquires SiteWorks Solutions to capitalize on drug companies that need to run clinical trials.
<Older 991-1000 Newer> Return to current articles.